Loading…
Avantor, Inc.
Avantor, Inc. (AVTR) is listed on NYSE and classified in Medical Instruments & Supplies, part of the Healthcare sector. It is headquartered in Radnor, United States and has 13,500 employees. The company is worth $11.6B. Revenue was $6.55B in fiscal 2025, down 3.4% from the year before. It reported a net loss of $530.2M. The share price is within 3% of its 52-week high. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $115.11M. In that quarter, 3 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -58.4% over 5Y.
today you would have $406.64▼ -59.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 7 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $11.46 | $21.07 | $22.83 | $21.09 | $42.14 | $28.15 | $18.15 | |
| P/E | 34.7x | — | 20.3x | 48.6x | 20.9x | 49.6x | 312.8x | — |
| P/S | 2.1x | 1.2x | 2.1x | 2.2x | 1.9x | 3.5x | 2.6x | 1.7x |
| P/B |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CORTCorcept Therapeutics Inc | $107.50 | 238.9x | 16.4x | 0.00% | 8.23% | $11.62B |
| TEMTempus AI, Inc. | $63.81 | — | 25.8x | 0.00% | -67.44% | $11.51B |
| COOCooper Companies Inc | $61.65 | 20.3x | 1.4x | 0.00% | 6.84% | $11.72B |
| TECHBIO-TECHNE Corp | $72.62 |
| 2.9x |
| 1.4x |
| 2.4x |
| 2.9x |
| 2.9x |
| 6.1x |
| 6.1x |
| 4.2x |
| EPS | -$0.78 | $1.04 | $0.47 | $1.01 | $0.85 | $0.09 | -$0.84 |
| Profit margin | 4.61% | -8.09% | 10.49% | 4.61% | 9.14% | 7.75% | 1.82% | 0.63% |
| ROE | 6.11% | -9.53% | 11.94% | 6.11% | 14.14% | 13.64% | 4.36% | 1.54% |
Median of the years shown; P/E years above 200x are left out.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
1 methods answered, across 1 families.
Room for errors in the reported numbers.
+14.1% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 62.6x |
| 5.4x |
| 0.44% |
| 9.03% |
| $11.39B |
| FMSFresenius Medical Care AG | $22.23 | 11.1x | 0.8x | 3.91% | 8.52% | $11.83B |
| RGENRepligen Corp | $178.71 | 244.8x | 4.8x | 0.00% | 1.99% | $11.35B |
